

Insert new claim 34 as follows:

--34. A method in accordance with claim 6, wherein said administering step comprises bringing said interferon into contact with the mucosa lining the mouth and/or throat of the mammal being treated.

Delete claims 17-20 and substitute therefor new claims 35-38 as follows:

C
B2
--35. An interferon composition for oromucosal contact, comprising a stimulating amount of interferon greater than ~~about~~ 20×10^6 IU, said amount exceeding that amount which would elicit a pathological response when parenterally administered, and a vehicle or excipient which facilitates contact with the mucosa lining the mouth or throat upon administration, said composition being in the form of a lozenge or buccal tablet.

C
--36. An interferon composition in accordance with claim 35, wherein said stimulating amount of interferon is ^{greater than} ~~about~~ 20×10^6 IU to about 1000×10^6 IU.

C
--37. An interferon composition in accordance with claim 35, wherein said stimulating amount of interferon is ^{greater than} ~~about~~ 20×10^6 to about 500×10^6 IU.

--38. An interferon composition in accordance with claim 35, wherein said stimulating amount of interferon is about 50×10^6 to about 500×10^6 IU.--

REMARKS

Claims 6, 13, and 22-38 presently appear in this case.

No claims have been allowed. The present amendment is intended to